MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Does Ultragenyx's Latest FDA Clearance Mean for Investors

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does FDA Clearance Mean for AI-Powered Diagnostics

2 months ago

What Does Teva's Recent FDA Acceptance Mean for Investors

4 months ago

What Does BriaCell's Latest Offering Mean for Investors

1 months ago

What Does EPRT's Latest Debt Offering Mean for Investors

1 months ago

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

Ionis Pharmaceuticals received FDA approval for TRYNGOLZA to treat severe hypertriglyceridemia and reduce acute pancreatitis risk, expanding its commercial pipeline.

IONS

Stock News•2 weeks ago

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

Ultragenyx reaffirmed 2026 revenue guidance of $730–$760M despite a Q1 net loss and Phase 3 failure, as it shifts to a focused rare disease platform with four approved products and key H2 2026 PDUFA d...

RARE

Stock News•3 weeks ago

This Biotech Stock Is Surging 66% on Surprise Good News From FDA

uniQure shares surged 66% after the FDA cleared its gene therapy for Huntington's disease to proceed toward marketing, removing a key regulatory hurdle.

QURE

Stock News•2 months ago

Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?

ADMA Biologics shares are in focus after the FDA expanded the label for Asceniv to include younger patients. This regulatory approval broadens the drug's addressable market and strengthens the company...

ADMA